<DOC>
	<DOCNO>NCT00767676</DOCNO>
	<brief_summary>Contact sensitization patch application .</brief_summary>
	<brief_title>Contact Sensitization Potential 828 Ointment</brief_title>
	<detailed_description>Single site study evaluate contact sensitization potential 828 ointment repetitive patch application skin normal , healthy volunteer .</detailed_description>
	<criteria>1 . SUBJECTS 1.1 SUBJECT POPULATION Subjects normal , healthy volunteer gender age 18 65 year . Subjects must satisfy follow criterion : 1 . Subjects must ambulatory , 18 65 year age reasonably good health ( physical require ) . 2 . Subjects may race skin type provide skin pigmentation interfere evaluation . 3 . Female subject must surgically sterile , postmenopausal use acceptable method birth control . 4 . Minor deviation normal medical history consider clinically significant investigator sponsor permit . 5 . Subjects must refrain sunbathing , use tan salon , swimming , use hot tub entire study . 6 . Bathing permitted subject must agree try keep patch dry possible . 7 . Subjects must read sign informed consent statement . 8 . All female child bear potential must agree take entry exit urine pregnancy test Subjects follow condition eligible participation : 1 . Any systemic disease disorder , complicate factor structural abnormality would negatively affect conduct outcome study ( i.e. , hepatitis , acute chronic renal insufficiency ) . 2 . Use prescribed pain medication , prescribe overthecounter antiinflammatory drug , immunosuppressive drug prescribe antihistamine medication ( steroid nose drop and/or eye drop permit ) . Use overthecounter pain medication ingest quantity exceed label instruction . 3 . Subjects receive investigational drug participate Draize type patch test within past 28 day currently participate plan enter clinical trial . 4 . A history noncompliance subject consider potentially unreliable . 5 . A history skin allergy , include know sensitivity strong reaction cosmetic and/or personal care product , topically prepared medical dressing , tape , adhesive . 6 . A history clinically significant skin disease may contraindicate participation , include psoriasis , active eczema ( test site ) , atopic dermatitis , active cancer , even currently control medication . 7 . Current use topical oral antibiotic . 8 . Use topical medication test area 2 week prior enrollment body lotions/oils/creams test area 48 hour prior enrollment throughout trial . 9 . Female subject pregnant , stop contraceptive measure , expect become pregnant breastfeeding . 10 . Subjects condition know interfere absorption , distribution , metabolism , excretion drug . 11 . Subjects hematological disorder immunologic disorder ( HIV positive , AIDS , Systemic Lupus Erythematosus ) . 12 . Subjects significant organ abnormality disorder include gastric ulcer/insulin dependent diabetes . 13 . Subjects clinically significant illness ( sought medical attention , fever , take prescription medication ) within 4 week prior study entry . 14 . History asthma , chronic bronchitis bronchospastic condition require medication . 15 . Anticipated change use systemic medication study may affect conduct outcome study . Subjects must stabilize medication least one month prior receive study drug continue regimen throughout study . 16 . Bilateral mastectomy cancer involve removal lymph node . 17 . Treatment type cancer within last six month . 18 . The Investigator may declare subject ineligible sound medical reason . 19 . Subjects allergies/known sensitivity ingredient test article .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Contact sensitization</keyword>
	<keyword>Healthy Adult Volunteers</keyword>
</DOC>